Tarsus Pharmaceuticals, Inc.
TARS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $119 | $103 | $78 | $66 |
| % Growth | 15.6% | 31.1% | 18% | – |
| Cost of Goods Sold | $25 | $6 | $5 | $5 |
| Gross Profit | $94 | $96 | $73 | $61 |
| % Margin | 79.3% | 93.9% | 93.3% | 92.6% |
| R&D Expenses | $16 | $16 | $14 | $17 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $109 | $103 | $85 | $69 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$16 | $0 | $0 | $0 |
| Operating Expenses | $109 | $119 | $99 | $86 |
| Operating Income | -$15 | -$22 | -$26 | -$24 |
| % Margin | -12.2% | -21.6% | -33.5% | -36.8% |
| Other Income/Exp. Net | $2 | $2 | $1 | $1 |
| Pre-Tax Income | -$13 | -$20 | -$25 | -$23 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$13 | -$20 | -$25 | -$23 |
| % Margin | -10.6% | -19.8% | -32.1% | -34.8% |
| EPS | -0.3 | -0.48 | -0.64 | -0.6 |
| % Growth | 37.5% | 25% | -6.7% | – |
| EPS Diluted | -0.3 | -0.48 | -0.64 | -0.6 |
| Weighted Avg Shares Out | 43 | 42 | 39 | 39 |
| Weighted Avg Shares Out Dil | 43 | 42 | 39 | 39 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $4 | $3 | $4 |
| Interest Expense | $0 | $2 | $2 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$12 | -$18 | -$22 | -$20 |
| % Margin | -10.2% | -17.2% | -28.7% | -30.7% |